3451. Tivicay-H-C-PSUSA-00010075-202001 3452. Pregabalin Pfizer-H-C-PSUSA-00002511-202001: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation 3453. EndolucinBeta-PSUSA-00010391-201912 3454. Onpattro-H-C-PSUSA-00010715-202002 3455. Saxenda-H-C-PSUSA-00001892-201912 3456. Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation 3457. Nimenrix-H-C-PSUSA-00010044-202004 3458. Byetta-PSUSA-00009147-202003 3459. Inbrija-H-C-PSUSA-00107800-202006 3460. Bortezomib Fresenius Kabi-H-C-PSUSA-00000424-202004 3461. Lysodren-H-C-521-PSUSA-00002075-202004 3462. Fycompa-H-C-PSUSA-00009255-202007: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation 3463. Angiotensin-II-receptor antagonists (sartans) : Scientific conclusions - Impact of the Article 5(3) scientific opinion on nitrosamines 3464. Trulicity-H-C-PSUSA-10311-202009 3465. Rydapt-H-C-PSUSA-00010638-202010 3466. Adakveo-H-C-PSUSA-00010888-202011 3467. Revlimid-H-C-PSUSA-00001838-202012 3468. Stelara-H-C-PSUSA-00003085-202012 : Scientific conclusions and grounds for the variation to the terms of the marketing authorisation 3469. Tecfidera-H-C-PSUSA-00010143-202103 3470. Lumigan-H-C-PSUSA-00000413-202103 3471. Ultomiris-H-C-PSUSA-00010787-202106 3472. Mysimba-H-C-PSUSA-00010366-202109: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation 3473. MabThera-H-C-PSUSA-00002652-202111 3474. Xalkori-PSUSA-00010042-202108 3475. Vemlidy-H-C-PSUSA-00010575-202111 3476. Lutathera-H-C-PSUSA-00010643-2202112 3477. Evrenzo-H-C-PSUSA-00010955-202112 3478. Yescarta-H-C-PSUSA-00010703-202110 3479. Oyavas-H-C-PSUSA-00000403-202202 3480. Alymsys-H-C-PSUSA-00000403-202202